Tofacitinib for the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 8, Issue 4, 2012, Pages 319-331

  Zerbini, Cristiano A F ^a   Lomonte, Andrea Barranjard Vannucci ^a  

^a HOSPITAL HELIÓPOLIS   (Brazil)

Author keywords

JAK inhibition; janus kinase inhibition; mechanism of action; rheumatoid arthritis; tofacitinib; treatment

Indexed keywords

ABATACEPT; ADALIMUMAB; BARICITINIB; BMS 582949; CERTOLIZUMAB PEGOL; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOSTAMATINIB; GAMMA INTERFERON; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STROMELYSIN; TOCILIZUMAB; TOFACITINIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; VX 509; VX 702;

ACUTE PYELONEPHRITIS; ANEMIA; ANGIOGENESIS; AREA UNDER THE CURVE; ARTHRALGIA; ATHEROSCLEROSIS; B CELL LYMPHOMA; BRONCHITIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; COMPETITIVE INHIBITION; CYTOKINE PRODUCTION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRY EYE; EFFECTOR CELL; ENTERITIS; FOLLOW UP; GASTROENTERITIS; HEART ARREST; HEART FAILURE; HUMAN; HYPERKALEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; INFECTION; INFECTIOUS ARTHRITIS; INFLUENZA; INNATE IMMUNITY; KIDNEY GRAFT REJECTION; LEUKOPENIA; LONG TERM CARE; LUNG EMBOLISM; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTOPENIA; MACROPHAGE; MAST CELL; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NATURAL KILLER CELL; NAUSEA; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMONIA; PSORIASIS; PSORIATIC ARTHRITIS; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; SINUSITIS; SYNOVIUM; T CELL LYMPHOMA; TH1 CELL; TH17 CELL; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URINARY TRACT INFECTION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; JANUS KINASE 3; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 84861390265     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.19     Document Type: Review

References (55)

1. Arnett FC, Edworthy SM, Bloch DA et al. The American rheumatism association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum. 31, 315-324 (1988).
2. Firestein G. Evolving concepts of rheumatoid arthritis. Nature 423, 356-361 (2003).
3. Steinman L. A brief history of TH17, the first major revision in the Th1/Th2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13, 139-145 (2007).
4. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204, 1849-1856 (2007).
5. Sato K, Suematsu A, Okamoto K et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673-2682 (2006).
6. Kirkham BW, Lassere MN, Edmonds JP et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 54, 1122-1131 (2006).
7. Liepe J, Skapenko A, Lipsky P et al. Regulatory T cells in rheumatoid arthritis. Arthritis Res. Ther. 7, 93-99 (2005).
8. Nadkarni S, Mauri C, Ehrenstein MR. Anti- TNF-a therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-b. J. Exp. Med. 204, 33-39 (2007).
9. Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: Rheumatoid arthritis and systemic sclerosis. Arthritis Res. Ther. 9(Suppl. 2), S3 (2007).
10. Lee DM, Kiener HP, Agarwal SK et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 315, 1006 (2007).
11. McInnes IB, Liew FY. Cytokine networks: towards new therapies for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 1, 31 (2005).
12. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26-37 (2006).
13. Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46, 1443-1450 (2002).
14. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41(9), 1552-1563 (1998).
15. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50(6), 1761-1769 (2004).
16. Darnell JE Jr, Kerr IM, Stark GR. JAK-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 3, 264(5164), 1415-1421 (1994).
17. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol. Rev. 228(1), 273-287 (2009).
18. Leonard WJ, O'Shea JJ. Jacks and STATs: biological implications. Annu. Rev. Immunol. 16, 29-322 (1998).
19. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by g(c) family cytokines. Nat. Rev. Immunol. 9, 480-490 (2009).
20. Bhan, Dari R, Kuriyan J. JAK-STAT signaling. In: Handbook of Cell Signaling (1st Edition). Bradshaw R, Dennis E (Eds). Academic Press, NY, USA, 343-347 (2003).
21. Russell SM, Tayebi N, Nakajima H et al. Mutation of JAK3 in a patient with SCID: essential role of JAK3 in lymphoid development. Science 270, 797-800 (1995).
22. Nosaka T, van Deursen JM, Tripp RA et al. Defective lymphoid development in mice lacking JAK3. Science 270, 800-802 (1995).
23. Changelian PS, Flanagan ME, Ball DJ et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875-878 (2003).
24. Flanagan ME, Blumenkopf TA, Brissette WH et al. Discovery of CP-690,550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J. Med. Chem. 53(24), 8468-8484 (2010).
25. Karaman MW, Herrgard S, Treiber DK et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
26. Meyer DM, Jesson MI, Li X et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J. Inflamm. 7, 41 (2010).
27. Chrencik JE , Patny A, Leung IK et al. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP- 690550 and CMP-6. J. Mol. Biol. 400, 413-433 (2010).
28. Krishnaswami S, Kudlacz E, Yocum S et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of CP-690,550 a Janus kinase inhibitor. AAPS J. 11, 36 (2009) (Abstract).
29. Chow V, Ni G, LaBadie R et al. Open label study to estimate the effect fluconazole on the pharmacokinetics of a JAK3 antagonist (CP-690, 550) in the healthy adult subjects. Clin. Pharmacol. Ther. 83, PI-93 (2008) (Abstract).
30. Chow V, Wilkinson B, LaBadie R et al. Open label study of the pharmacokinetics of a JAK3 antagonist (CP-690,550) and single doses of a oral methotrexate in rheumatoid arthritis subjects. Clin. Pharmacol. Ther. 83, PI-92 (2008) (Abstract).
31. Chow V, Krishnaswami S, Chan G. Pharmacokinetics of CP-690,550, a janus kinase inhibitor, in subjects with impaired renal function and end-stage renal disease. Clin. Pharmacol. Ther. 85, PII-86 (2009) (Abstract).
32. Milici AJ, Kudlacz EM, Audoly L et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res. Ther. 10(1), R14 (2008).
33. Ghoreschi K, Jesson MI, Li X et al. Modulation of innate and adptative immune responses by tofacitinib (CP- 690,550). J. Immunol. 186, 4234-4243 (2011).
34. Borie DC, Larson MJ, Flores MG et al. Combined use of the JAK3 inhibitor CP- 690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. Transplantation 80(12), 1756-1764 (2005
35. Kudlacz E, Perry B, Sawyer P et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am. J. Transplant. 4(1), 51-57 (2004).
36. Corry R, Winn H, Russel P. Primarily vascularized allografts of hearts in mice. Transplantation 16(4), 343-353 (1973).
37. Babany G, Morris RE, Babany I et al. Evaluation of the in vivo dose-response relationship of immunosuppressive drugs using a mouse heart transplant model: Application to cyclosporine. J. Pharmacol. Exp. Ther. 244(1), 259-262 (1988).
38. Borie DC, Hausen B et al. Nonhuman primates to study the effects of immunosuppressive drugs: Report of a life-supporting technique of renal allotransplantation in Macaca fascicularis. J. Surg. Res. 107, 64-74 (2002).
39. Borie DC, Changelian PS, Larson MJ et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 79, 791-802 (2005).
40. Kremer JM, Bloom BJ, Breedveld FC et al. The safety and efficacy of a JAK inhibitor in patient with active rheumatoid arthritis - results of a double-blind, placebo-controlled Phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60(7), 1895-1905 (2009).
41. Coombs JH, Bloom BJ, Breedveld FC et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: Results from a randomized, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 69, 413-416 (2010).
42. Kremer JM, Cohen S, Wilkinson BE et al. A Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 64(4), 970-981 (2012).
43. Fleischmann R, Cutolo M, Genovese MC et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 64(3), 617-629 (2012).
44. Tanaka Y, Suzuki M, Nakamura H et al. Phase 2 study of tofacitinib (CP-690, 550) combined with methotrexate in patients with rheumatoid arthritis and inadequate response to methotrexate. Arthritis Care Res. (Hoboken) 63(8), 1150-1158 (2011).
45. Fleischmann R, Kremer J, Cush J et al. Phase 3 study of oral JAK inhibitor tasocitinib (CP-690,550) monotherapy in patients with active rheumatoid arthritis. Presented at: Annual Scientific Meeting of the American College of Rheumatology. Atlanta, GA, USA, 6-11 November 2010 (Abstract 4352).
46. van Der Heijde D, Tanaka Y, Fleischmann R et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: A 24 month Phase 3 study. Arthritis Rheum. 63(S1017), 2592 (2011) (Abstract).
47. Burmester G, Blanco R, Charles- Schoemann C et al. Tofacitinib (CP- 690,550), an oral janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor-inhibitors: A 6 month Phase 3 study. Arthritis Rheum. 63(S279), 718 (2011) (Abstract).
48. Connell CA, Riese RJ, Wood SP et al. Tasocitinib (CP-690,550), an orally available selective janus kinase inhibitor, exhibits sustained safety and efficacy in the treatment of rheumatoid arthritis over 24 months. Artrhtis Rheum. 62(S473), 1129 (2010) (Abstract).
49. Connell CA, Riese RJ, Wood SP et al. Tasocitinib (CP-690,550) appears to be effective and tolerated when administered either as long-term monotherapy or on background methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 62(S911), 2171 (2010) (Abstract).
50. Wollenhaupt J, Silverfield JC, Lee EB et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension studies up to 36 months. Arthritis Rheum. 63(Suppl. 10), S152-S153 (2011) (Abstract 407).
51. Cohen S, Radominski SC, Asavatanabodee P et al. Tofacitinib (CP-690,550), an oral Janus Kinase inhibitor: Analysis of infections and all-cause mortality across Phase 3 and long-term extension studies in patients with rheumatoid arthritis. Arthritis Rheum. 63(Suppl. 10), S153 (2011) (Abstract 409).
52. van De Sande MGH, De Hair MJH, van Der Leij C et al. Different stages of rheumatoid arthritis: features of the sinovium in the preclinical phase. Ann. Rheum. Dis. 70, 772-777 (2011).
53. Machado P, Castrejon I, Katchamart W et al. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann. Rheum. Dis. 70, 15-24 (2011).
54. Opar A. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat. Rev. Drug Discov. 9(4), 257-258 (2010).
55. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3(11), 900-911 (2003).